SAVA241018P23500
- 0.06
- -0.12-66.67%
Cassava Sciences Newsroom
10 Health Care Stocks With Whale Alerts In Today's Session
Daily options tracking | Nvidia refreshes historical highest closing price, multiple Friday expiration call options doubled; U.S. version of Huabei SOFI surged 11%, one call option made a whopping 13 times profit.
Cryptos surged, with a significant increase in options volume for related concept stocks. Among them, Coinbase rose by 11.32%, with an options volume of 0.5797 million contracts, and a call ratio of 84.4%.
Daily options tracking | Tesla plunges nearly 6% in pre-market trading! Large bearish options orders appeared the night before the conference; Trump media soared over 17% overnight, many bullish call options gained more than 3 times.
AMD has launched a new version of AI accelerator MI325X, with a sharp 4% drop in stock price. Options trading volume significantly increased compared to the previous trading day, with the call ratio rising to 70.6%.
Daily options recap | Apple closes up nearly 2%, Friday's call options with the highest profit reaching 150%; SPY, QQQ put options ratio increases, now tens of millions of dollars large order selling call options.
Nvidia fell slightly by 0.18%, the call ratio rose to 62.7%; In Nvidia options, the highest number of unclosed call options with a strike price of $110 expiring on December 30 this year reached 0.203 million contracts.
$1000 Invested In This Stock 5 Years Ago Would Be Worth $20,000 Today
Sector Update: Health Care Stocks Rise Late Afternoon
Cassava Sciences Completes Phase 3 ReTHINK Alzheimer's Trial
Cassava Sciences Stock Jumps After CEO's Update On Alzheimer's Drug Trial: Retail Sentiment Wavers
Crude Oil Falls Over 4%; US Trade Deficit Narrows In August
What's Going On With Alzheimer's-Focused Cassava Sciences On Tuesday?
PepsiCo, DocuSign, Robinhood And Other Big Stocks Moving Higher On Tuesday
This Wells Fargo Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Nano-Cap Bio-Path Takes Plunge In Weight Loss Race, Initiates Obesity Program With Drug Candidate Under Development For Blood Cancer
Cassava Sciences Earns Rare Buy as H.C. Wainwright Upgrades Post Settlement
H.C. Wainwright Upgrades Cassava Sciences(SAVA.US) to Buy Rating, Announces Target Price $116
Express News | Cassava Shares up 6.3% Premarket After Co Decides to Settle SEC Charges on Alzheimer's Drug Trial Claims
Cassava Sciences Advances Alzheimer's Trials Amid SEC Settlement
Cassava Sciences Price Target Announced at $116.00/Share by HC Wainwright & Co.
Cassava Sciences CEO Rick Barry Issues Open Letter
Express News | Cassava Sciences- Agreed to Settle Charge of 'negligently Making Inaccurate Disclosures' Related to 2020 Phase 2B Clinical Study